Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | FKBP1A | P62942 | 6/20 | 0.45 |
| ▸ | POLB | P06746 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23153566 | 0.78 | L3MBTL1 (0.71) | L3MBTL1FKBP1APOLBALDH1A1TSHR | |
| SCHEMBL12439630 | 0.78 | L3MBTL1 (0.78) | L3MBTL1FKBP1APOLBALDH1A1TSHR | |
| SCHEMBL28685062 | 0.78 | L3MBTL1 (0.66) | L3MBTL1KDM4EFKBP1APOLBALDH1A1 | |
| SCHEMBL24313327 | 0.78 | L3MBTL1 (0.78) | L3MBTL1FKBP1APOLBALDH1A1TSHR | |
| SCHEMBL428816 | 0.78 | L3MBTL1 (0.78) | L3MBTL1FKBP1APOLBALDH1A1TSHR | |
| SCHEMBL14538081 | 0.77 | L3MBTL1 (0.70) | L3MBTL1FKBP1APOLBALDH1A1TSHR | |
| SCHEMBL1726021 | 0.76 | L3MBTL1 (0.68) | L3MBTL1FKBP1APOLBALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL3724641 | 0.76 | L3MBTL1 (0.68) | L3MBTL1FKBP1APOLBALDH1A1TSHR | |
| SCHEMBL10786869 | 0.76 | L3MBTL1 (0.68) | L3MBTL1FKBP1APOLBALDH1A1TSHR | |
| SCHEMBL9124397 | 0.75 | L3MBTL1 (0.72) | L3MBTL1FKBP1APOLBALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160046584-A1 | COMPOSITIONS AND METHODS OF USING THE COMPOSITIONS FOR PLAQUE SOFTENING | ALUMEND, LLC (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160030413-A1 | METHODS OF ACUTE RESTORATION OF VASCULAR COMPLIANCE | ALUMEND, LLC (US) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030413-A1 | METHODS OF ACUTE RESTORATION OF VASCULAR COMPLIANCE | APOB, LIPG, VCAM1 | L3MBTL1 3583/4885KDM4E 2677/4885FKBP1A 3892/4885 |
| US-20160046584-A1 | COMPOSITIONS AND METHODS OF USING THE COMPOSITIONS FOR PLAQUE SOFTENING | APOB, PLG, LIPG | L3MBTL1 4709/4885KDM4E 3988/4885FKBP1A 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.